Portage Biotech’s (ALP) “Neutral” Rating Reiterated at HC Wainwright

Portage Biotech (NASDAQ:ALP)‘s stock had its “neutral” rating restated by equities research analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $0.25 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 44.18% from the company’s current price.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Portage Biotech in a report on Friday, July 24th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Portage Biotech has an average rating of “Reduce” and a consensus target price of $0.25.

Portage Biotech Price Performance

Shares of ALP opened at $0.17 on Monday. The stock has a market cap of $4.07 million, a P/E ratio of -0.02 and a beta of 0.61. Portage Biotech has a 1 year low of $0.15 and a 1 year high of $13.80. The stock’s 50-day moving average price is $0.29 and its two-hundred day moving average price is $0.35. The company has a current ratio of 0.31, a quick ratio of 0.31 and a debt-to-equity ratio of 0.01.

Portage Biotech (NASDAQ:ALP) last released its quarterly earnings data on Thursday, July 16th. The company reported $0.48 earnings per share for the quarter. The firm had revenue of $0.05 million for the quarter.

Portage Biotech Company Profile

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.